348 related articles for article (PubMed ID: 32956996)
21. Small interfering RNA-mediated suppression of serum response factor, E2-promotor binding factor and survivin in non-small cell lung cancer cell lines by non-viral transfection.
Walker T; Nolte A; Steger V; Makowiecki C; Mustafi M; Friedel G; Schlensak C; Wendel HP
Eur J Cardiothorac Surg; 2013 Mar; 43(3):628-33; discussion 633-4. PubMed ID: 23152437
[TBL] [Abstract][Full Text] [Related]
22. Target-specific delivery of siRNA by stabilized calcium phosphate nanoparticles using dopa-hyaluronic acid conjugate.
Lee MS; Lee JE; Byun E; Kim NW; Lee K; Lee H; Sim SJ; Lee DS; Jeong JH
J Control Release; 2014 Oct; 192():122-30. PubMed ID: 24995950
[TBL] [Abstract][Full Text] [Related]
23. Facile preparation of calcium phosphate nanoparticles for siRNA delivery: effect of synthesis conditions on physicochemical and biological properties.
Zhang M; Lin W; Lin B; Huang Y; Lin H; Qul J
J Nanosci Nanotechnol; 2012 Dec; 12(12):9029-36. PubMed ID: 23447954
[TBL] [Abstract][Full Text] [Related]
24. Design and anti-tumor activity of self-loaded nanocarriers of siRNA.
Han W; Yuan Y; Li H; Fu Z; Wang M; Guan S; Wang L
Colloids Surf B Biointerfaces; 2019 Nov; 183():110385. PubMed ID: 31408781
[TBL] [Abstract][Full Text] [Related]
25. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
[No Abstract] [Full Text] [Related]
26. Highly stable polyglutamate derivatives/siRNA polyplex efficiently down-relegate survivin expression and augment the efficacy of cisplatin.
Wang Z; Zou H; Wang Z; Wu J; Xia Z; Feng M
Int J Pharm; 2016 May; 505(1-2):24-34. PubMed ID: 27039150
[TBL] [Abstract][Full Text] [Related]
27. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and Characterization of a New Cationic Lipid: Efficient siRNA Delivery and Anticancer Activity of Survivin-siRNA Lipoplexes for the Treatment of Lung and Breast Cancers.
Vaidya S; Mohod A; Eedara AC; Andugulapati SB; Pabbaraja S
ChemMedChem; 2023 Aug; 18(16):e202300097. PubMed ID: 37306531
[TBL] [Abstract][Full Text] [Related]
29. Bioreducible Cross-Linked Hyaluronic Acid/Calcium Phosphate Hybrid Nanoparticles for Specific Delivery of siRNA in Melanoma Tumor Therapy.
Zhou Z; Li H; Wang K; Guo Q; Li C; Jiang H; Hu Y; Oupicky D; Sun M
ACS Appl Mater Interfaces; 2017 May; 9(17):14576-14589. PubMed ID: 28393529
[TBL] [Abstract][Full Text] [Related]
30. Systemic delivery of sticky siRNAs targeting the cell cycle for lung tumor metastasis inhibition.
Bonnet ME; Gossart JB; Benoit E; Messmer M; Zounib O; Moreau V; Behr JP; Lenne-Samuel N; Kedinger V; Meulle A; Erbacher P; Bolcato-Bellemin AL
J Control Release; 2013 Sep; 170(2):183-90. PubMed ID: 23727288
[TBL] [Abstract][Full Text] [Related]
31. Apoptosis induction activity and molecular docking studies of survivin siRNA carried by Fe
Arami S; Mahdavi M; Rashidi MR; Yekta R; Rahnamay M; Molavi L; Hejazi MS; Samadi N
J Pharm Biomed Anal; 2017 Aug; 142():145-154. PubMed ID: 28505590
[TBL] [Abstract][Full Text] [Related]
32. Fatty acid modified octa-arginine for delivery of siRNA.
Li Y; Li Y; Wang X; Lee RJ; Teng L
Int J Pharm; 2015 Nov; 495(1):527-535. PubMed ID: 26386137
[TBL] [Abstract][Full Text] [Related]
33. Reduction of inflammation in a chronic periodontitis model in rats by TNF-α gene silencing with a topically applied siRNA-loaded calcium phosphate paste.
Tenkumo T; Rojas-Sánchez L; Vanegas Sáenz JR; Ogawa T; Miyashita M; Yoda N; Prymak O; Sokolova V; Sasaki K; Epple M
Acta Biomater; 2020 Mar; 105():263-279. PubMed ID: 31982590
[TBL] [Abstract][Full Text] [Related]
34. Development of a carrier system containing hyaluronic acid and protamine for siRNA delivery in the treatment of melanoma.
Yang J; Zhao R; Feng Q; Zhuo X; Wang R
Invest New Drugs; 2021 Feb; 39(1):66-76. PubMed ID: 32794135
[TBL] [Abstract][Full Text] [Related]
35. Combination Therapy of Breast Cancer by Codelivery of Doxorubicin and Survivin siRNA Using Polyethylenimine Modified Silk Fibroin Nanoparticles.
Norouzi P; Motasadizadeh H; Atyabi F; Dinarvand R; Gholami M; Farokhi M; Shokrgozar MA; Mottaghitalab F
ACS Biomater Sci Eng; 2021 Mar; 7(3):1074-1087. PubMed ID: 33539074
[TBL] [Abstract][Full Text] [Related]
36. Targeted silencing of Survivin in cancer cells by siRNA loaded chitosan magnetic nanoparticles.
Unsoy G; Gunduz U
Expert Rev Anticancer Ther; 2016 Jul; 16(7):789-97. PubMed ID: 27130312
[TBL] [Abstract][Full Text] [Related]
37. Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis.
Yang Y; Li J; Liu F; Huang L
Mol Ther; 2012 Mar; 20(3):609-15. PubMed ID: 22186791
[TBL] [Abstract][Full Text] [Related]
38. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
39. Dual Functional LipoMET Mediates Envelope-type Nanoparticles to Combinational Oncogene Silencing and Tumor Growth Inhibition.
Shi K; Zhao Y; Miao L; Satterlee A; Haynes M; Luo C; Musetti S; Huang L
Mol Ther; 2017 Jul; 25(7):1567-1579. PubMed ID: 28274796
[TBL] [Abstract][Full Text] [Related]
40. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
Li SD; Huang L
Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
